Dyne Therapeutics Inc. (DYN) shares plummeted 5.08% during intraday trading on Tuesday, as the stock faced significant selling pressure.

The decline followed downward revisions to the company's price targets by multiple Wall Street analysts. Morgan Stanley cut its target price on Dyne Therapeutics to $47.00 from $50.00, while H.C. Wainwright lowered its target to $50 from $60, though it maintained a Buy rating on the shares.

These analyst actions, which reflect adjusted expectations for the company's future performance, contributed to negative market sentiment and drove the stock's sharp decline during the trading session.